Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing and commercializing proprietary pharmaceuticals to treat cancer and other life-threatening disorders.

Cantex's pipeline features two products in Phase II clinical development. CX-02, a proprietary combination of disulfiram + copper, is in a Phase II trial for recurrent glioblastoma. Top-line results of this Phase II trial, as well as the initiation of additional Phase II trials in metastatic prostate cancer and breast cancer, are expected in the second half of 2017. 

CX-01 is being developed for the treatment of acute myeloid leukemia (AML) and other blood disorders. A randomized Phase IIB trial of CX-01 in newly diagnosed AML is currently enrolling patients. Separately, Cantex expects to initiate phase II trials in 2017 in patients with myelodysplastic syndrome, and in patients with severe traumatic brain injury.

 

Latest News

Spotlight

Cantex has two products in Phase II clinical development:

CX-02:

  • Highly active against glioblastoma, triple-negative breast cancer, and other malignant stem cells
  • Unique proprietary formulation combining two compounds with well-established safety
  • Phase II trial in recurrent glioblastoma undeway; additional Phase II trials in other malignancies to begin in 2017

 

CX-01:

  • Inhibits activity of HMGB1, a protein implicated in chemotherapy resistance and in several life-threatening inflammatory disorders
  • 75-patient randomized Phase IIB study in newly diagnosed AML now enrolling
  • Additional Phase II trials in myelodysplastic syndrome and traumatic brain injury in 2017